Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

CD19 CAR T-cells effective with with low dose chemotherapy.

Dr Stephanie Goff - National Cancer Institute, Bethesda, USA
CD19 CAR T-cells effective with with low dose chemotherapy. ( Dr Stephanie Goff - National Cancer Institute, Bethesda, USA )
12 Jun 2016

PD-1 enhances elotuzumab efficacy

Dr Natalie Bezman - Bristol-Meyers Squibb, Princeton, USA
PD-1 enhances elotuzumab efficacy ( Dr Natalie Bezman - Bristol-Meyers Squibb, Princeton, USA )
12 Jun 2016

The latest in CLL from EHA 2016

Prof Peter Hillmen, Prof Paolo Ghia, Dr Chris Fox and Dr Constantine Tam
The latest in CLL from EHA 2016 ( Prof Peter Hillmen, Prof Paolo Ghia, Dr Chris Fox and Dr Constantine Tam )
11 Jun 2016

Older patients with AML benefit greatly from SGN-CD33 and HMA therapy combo

Dr Amir Fathi, Massachusetts General Hospital, Boston, USA
Older patients with AML benefit greatly from SGN-CD33 and HMA therapy combo ( Dr Amir Fathi, Massachusetts General Hospital, Boston, USA )
11 Jun 2016

Killer antibodies against AML

Dr Mette Hazenberg - AMC, Amsterdam, The Netherlands
Killer antibodies against AML ( Dr Mette Hazenberg - AMC, Amsterdam, The Netherlands )
11 Jun 2016

Multiple myeloma highlights from EHA 2016

Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Paul Richardson, Prof Philip McCarthy
Multiple myeloma highlights from EHA 2016 ( Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Paul Richardson, Prof Philip McCarthy )
10 Jun 2016

SL401 in patients with rare neoplasm

Prof Naveen Pemmaraju - The University of Texas MD Anderson Cancer Center, Houston, United States
SL401 in patients with rare neoplasm ( Prof Naveen Pemmaraju - The University of Texas MD Anderson Cancer Center, Houston, United States )
10 Jun 2016

Daratumumab shows remarkable benefit in relapsed or refractory MM

Prof Meletios Dimopoulos - University Athens School of Medicine, Athens, Greece
Daratumumab shows remarkable benefit in relapsed or refractory MM ( Prof Meletios Dimopoulos - University Athens School of Medicine, Athens, Greece )
10 Jun 2016

Blinatumomab improves survival in ALL patients

Prof Max Topp - University of Würzburg, Würzburg, Germany
Blinatumomab improves survival in ALL patients ( Prof Max Topp - University of Würzburg, Würzburg, Germany )
10 Jun 2016

Stopping tyrosine kinase inhibitors in CML

Dr Johan Richter - Lund University, Sweden
Stopping tyrosine kinase inhibitors in CML ( Dr Johan Richter - Lund University, Sweden )
10 Jun 2016

Evaluation of ibrutinib in treatment of CLL with 17p deletion

Dr Jeffrey Jones - OSU James Cancer Hospital, Columbus, USA
Evaluation of ibrutinib in treatment of CLL with 17p deletion ( Dr Jeffrey Jones - OSU James Cancer Hospital, Columbus, USA )
10 Jun 2016

Nivolumab restores effective anti-tumour response in Hodgkin lymphoma

Dr Anas Younes - Memorial Sloan Kettering Cancer Centre, New York, USA
Nivolumab restores effective anti-tumour response in Hodgkin lymphoma ( Dr Anas Younes - Memorial Sloan Kettering Cancer Centre, New York, USA )
10 Jun 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation